London, 21 August 2015: Technavio, the independent tech-focused global research firm, has published a report on the global dry eye syndrome market 2015-2019, which is expected to grow at a CAGR of 4.75% during the forecast period of 2014-2019.
Deficient tear production, quick tear evaporation, or deviation in tear uniformity causes dryness in the eyes, leading to the dry eye syndrome. The syndrome is of two types: aqueous tear-deficient dry eye and evaporative dry eye. In the aqueous tear-deficient dry eye, the lacrimal glands produce less tears while the evaporative dry eye is caused by the dysfunction of the meibomian glands, which slow down the evaporation of tears and maintain tear stability.
“There is a need for new drugs that control inflammation with improved efficacy or stimulate mucin and tear secretion,” says Faisal Ghaus, Vice President of Technavio.
“Owing to the high prevalence and incidence rates, the reimbursement plans for the US are expected to affect the global dry eye scenario. The US government’s social insurance program, Medicare, provides coverage to people for the diagnosis of dry eye syndrome.”
Key Market Drivers
- Medicare reimbursement
- Environmental factors
- Increase in aging population
- Increase in prevalence of dry eye syndrome
Key Market Trends
- Medicare reimbursement
- Environmental factors
- Increase in aging population
- Increase in prevalence of dry eye syndrome
Key Market Vendors
- Alcon
- Allergan
- Otsuka Holdings
- Santen Pharmaceuticals
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
